Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial
- 1 January 2003
- Vol. 61 (1) , 142-144
- https://doi.org/10.1016/s0090-4295(02)02097-6
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate CancerJournal of Clinical Oncology, 2001
- The Phase II/III TransitionControlled Clinical Trials, 2000
- Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate CancerJNCI Journal of the National Cancer Institute, 1999